| Approach | Ask before choosing |
|---|---|
| Controlled cooling | Compare applicator fit, cold-sensitivity exclusions and delayed review of a defined fat bulge; discuss PAH before consent. |
| Heat or ultrasound | Identify RF, light or therapeutic ultrasound, the measured outcome, skin or eye protection and burn or nerve-injury precautions. |
| Muscle stimulation | Clarify muscle-tone versus fat claims, implant exclusions and whether temporary effects mean ongoing paid sessions. |
| Injection-based treatment | Identify the product and permitted body site before price; distinguish the under-chin deoxycholic acid indication from abdominal packages. |
Cooling: a pinchable bulge, not a scale target
FDA describes cryolipolysis as controlled cooling of fat drawn into an applicator. Damaged fat is usually cleared over two to three months; that is a tissue-response interval, not a guaranteed result date. Discuss cold-sensitivity disorders, applicator fit, skin protection and the possibility of paradoxical fat enlargement before booking.
Heat and ultrasound: name the technology
Radiofrequency heats tissue and may temporarily change circumference, cellulite or skin appearance. Therapeutic ultrasound uses sound energy and requires complete skin contact with gel; burns and nerve injury are possible. Light-based heating is different again and requires eye protection. Ask whether the evidence measures fat thickness, circumference or skin appearance rather than treating those outcomes as interchangeable.
Muscle stimulation: a different endpoint
FDA describes pulsed magnetic fields as causing muscle contractions that may improve tone or firmness. The effect may be temporary and require ongoing procedures. Muscle soreness or cramps can occur, and active electronic or metal implants affect suitability. A stronger-looking muscle is not evidence of visceral-fat loss.
Injections: product and body site come first
Injection lipolysis breaks the skin and is not a non-invasive surface-device procedure. FDA's updated safety communication identifies Kybella and a generic deoxycholic acid product for moderate-to-severe fat-related fullness under the chin in adults. Kybella is not approved for fat elsewhere and that use is not recommended. Nodules, swallowing problems, nerve injury and tissue damage need a separate consent discussion; an abdominal injection package cannot borrow the under-chin indication.
Separate US evidence from UAE authorization
FDA clearance or approval is tied to a particular device or product, intended use and body site. It is not proof of UAE authorization, professional scope or availability at the linked provider. Request the exact name, current local regulatory evidence, proposed body area and alternatives, including no treatment. No device, injection product or clinic capability is verified by this guide.
A combined package is not automatically better. Each added treatment needs its own rationale, consent, recovery plan and total-cost explanation.
Sources: FDA — non-invasive body-contouring technologies; FDA — deoxycholic acid: approved area and updated safety warnings; FDA — harms from unapproved fat-dissolving injections
